- Publication status:
- Published
- Peer review status:
- Reviewed (other)
- Version:
- Accepted Manuscript
- Publisher:
- American Thoracic Society Publisher's website
- Volume:
- 199
- Pages:
- A3826
- Publication date:
- 2019-05-22
- Acceptance date:
- 2019-01-01
- EISSN:
-
1535-4970
- ISSN:
-
1073-449X
- Pubs id:
-
pubs:1003696
- URN:
-
uri:c2a94f0e-257e-4c1e-b780-25ce83bb347c
- UUID:
-
uuid:c2a94f0e-257e-4c1e-b780-25ce83bb347c
- Local pid:
- pubs:1003696
- Copyright holder:
- American Thoracic Society
- Copyright date:
- 2019
- Notes:
- This paper was presented at the American Thoracic Society 2019 International Conference, 17-22 May 2019, Dallas, TX USA. This is the accepted manuscript version of the article. The final version is available online from American Thoracic Society at: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3826
Conference item
Fevipiprant, a selective prostaglandin D(2)receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by Tc2 cells (type-2 CD8(+)lymphocytes)
Actions
Authors
Bibliographic Details
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record